UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 159 | +4 | 28.21M | $15.29B | +8 | −3 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | — |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | — | — |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | — |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | — | — |
| Q2 2024 | 14 | — | 8.17M | $2.60B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 3.29M | — | $1.05B | 0.2% | n/c | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 2.17M | — | $692.75M | 1.2% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passief) | 1.05M | — | $333.57M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passief) | 1.05M | — | $333.57M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 719.51K | — | $229.20M | 0.4% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 719.51K | — | $229.20M | 0.4% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 719.51K | — | $229.20M | 0.4% | n/c | 1 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 438.68K | — | $139.74M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 234.92K | — | $74.83M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 234.92K | — | $74.83M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 103.03K | — | $32.82M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 47.59K | — | $15.16M | 0.2% | n/c | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 42.02K | — | $13.39M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 42.02K | — | $13.39M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Norges Bank ✦ (passief) | 38.93K | — | $12.40M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Marshall Wace ✦ | 20.11K | — | $6.40M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Bridgewater Associates ✦ | 12.75K | — | $4.06M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Fisher Asset Management ✦ | 5.16K | — | $1.64M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Two Sigma Investments ✦ | 1.90K | — | $605,245 | 0.0% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 218.70K aandelen, $129,684 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 1.32K aand · $675,421
Officer, Director · 3.59K aand · $1.84M
Officer, Director · 224 aand · $114,108
Officer, Director · 3.06K aand · $1.56M
Officer, Director · 1.30K aand · $669,921
Officer, Director · 773 aand · $399,695
Officer, Director · 235 aand · $123,474
Officer, Director · 455 aand · $238,247
Officer, Director · 669 aand · $349,411
Officer, Director · 271 aand · $139,254
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie